NextCure, Inc. Schedule 13G/A Amendment discloses that a group of related Simcere entities and two individuals report beneficial interests totaling 338,636 shares of NextCure common stock, representing 9.4% of the class, based on 3,607,555 shares outstanding as of April 22, 2026. The filing is a joint amendment by Simcere Zaiming, Inc.; Jiangsu Simcere Zaiming Pharmaceutical Co., Ltd.; Simcere Zaiming Pharmaceutical Co., Ltd.; Simcere Pharmaceutical Group Limited; and Messrs. Ren and Tang, and includes a standard disclaimer that each Reporting Person disclaims beneficial ownership except for pecuniary interest.
Positive
None.
Negative
None.
Insights
Simcere-affiliated entities report a near double-digit stake in NextCure.
The filing shows 338,636 shares (9.4% of outstanding stock as of April 22, 2026) held through a chain of related entities. The structure ties beneficial ownership up through a Hong Kong-listed parent and two named executives, which is typical for cross-border strategic holders.
Key dependencies include the chain of ownership and the joint filing agreement dated August 19, 2025. Subsequent public filings may clarify whether the position is passive or strategic; current text includes a disclaimer limiting attribution to pecuniary interest.
Key Figures
Reported shares owned:338,636 sharesPercent of class:9.4%Shares outstanding:3,607,555 shares+1 more
4 metrics
Reported shares owned338,636 sharesAggregate holding reported by the Simcere reporting persons
Percent of class9.4%Calculated using shares outstanding as of April 22, 2026
Shares outstanding3,607,555 sharesShares outstanding as of April 22, 2026 cited in filing
Signature date05/06/2026Date signatures appear on the amendment
Key Terms
Schedule 13G/A, beneficially own, joint filing agreement, power of attorney
4 terms
Schedule 13G/Aregulatory
"Amendment No. 1 ) NextCure, Inc. Common Stock"
A Schedule 13G/A is an amended public filing with the U.S. securities regulator that updates a previous Schedule 13G, disclosing when an individual or group holds a substantial (typically over 5%) stake in a company and is claiming a passive, non‑controlling intent. Investors monitor these updates because rising or falling holdings can signal changing confidence, potential future moves, or shifts in voting power — like watching a public ledger where large shareholders quietly adjust their positions.
beneficially ownregulatory
"may deemed to beneficially own all of the shares"
Beneficially own means having the economic rights and risks of a security—such as the right to receive dividends, sell the shares, or profit from price changes—whether or not your name appears on the official share register. Think of it like renting a car: you use it and reap the benefits even if the title lists someone else. Investors care because beneficial ownership determines who truly controls value, must be disclosed under securities rules, and can signal potential influence or trading activity that affects a stock’s price.
joint filing agreementlegal
"The Reporting Persons have entered into a joint filing agreement dated August 19, 2025"
power of attorneylegal
"Power of Attorney (incorporated by reference to Exhibit 24)"
A power of attorney is a legal document that allows one person to make decisions and act on behalf of another person, often in financial or legal matters. It’s like giving someone a trusted helper or agent the authority to handle important tasks if you are unable to do so yourself. This matters to investors because it can impact how their assets are managed or transferred if they become unable to oversee their affairs.
See more from StockTitan in Google Search and AI answers.Adds StockTitan as a preferred source · opens Google
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13G
UNDER THE SECURITIES EXCHANGE ACT OF 1934
(Amendment No. 1)
NextCure, Inc.
(Name of Issuer)
Common Stock, par value $0.001 per share
(Title of Class of Securities)
65343E207
(CUSIP Number)
12/31/2025
(Date of Event Which Requires Filing of this Statement)
Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)
schemaVersion:
SCHEDULE 13G
CUSIP Number(s):
65343E207
1
Names of Reporting Persons
Simcere Zaiming, Inc.
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
DELAWARE
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
338,636.00
6
Shared Voting Power
0.00
7
Sole Dispositive Power
338,636.00
8
Shared Dispositive Power
0.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
338,636.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
9.4 %
12
Type of Reporting Person (See Instructions)
CO
Comment for Type of Reporting Person: Note to Rows (5), (7) and (9): Represents 338,636 shares of the Issuer's common stock held by Simcere Zaiming, Inc.
Note to Row (11): Based on an aggregate of 3,607,555 shares of the Issuer's common stock issued and outstanding as of April 22, 2026 as reported by the Issuer in its definitive proxy statement on Schedule 14A filed with the U.S. Securities and Exchange Commission on April 24, 2026.
SCHEDULE 13G
CUSIP Number(s):
65343E207
1
Names of Reporting Persons
Jiangsu Simcere Zaiming Pharmaceutical Co., Ltd.
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
CHINA
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
338,636.00
6
Shared Voting Power
0.00
7
Sole Dispositive Power
338,636.00
8
Shared Dispositive Power
0.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
338,636.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
9.4 %
12
Type of Reporting Person (See Instructions)
CO
Comment for Type of Reporting Person: Note to Rows (5), (7) and (9): Represents 338,636 shares of the Issuer's common stock held by Simcere Zaiming, Inc., which is 100% owned by Jiangsu Simcere Zaiming Pharmaceutical Co., Ltd. Pursuant to Section 13(d) of the Securities Exchange Act of 1934, as amended, and the rules promulgated thereunder, Jiangsu Simcere Zaiming Pharmaceutical Co., Ltd. may deemed to beneficially own all of the shares of the Issuer owned by Simcere Zaiming, Inc.
Note to Row (11): Based on an aggregate of 3,607,555 shares of the Issuer's common stock issued and outstanding as of April 22, 2026 as reported by the Issuer in its definitive proxy statement on Schedule 14A filed with the U.S. Securities and Exchange Commission on April 24, 2026.
SCHEDULE 13G
CUSIP Number(s):
65343E207
1
Names of Reporting Persons
Simcere Zaiming Pharmaceutical Co., Ltd.
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
CHINA
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
338,636.00
6
Shared Voting Power
0.00
7
Sole Dispositive Power
338,636.00
8
Shared Dispositive Power
0.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
338,636.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
9.4 %
12
Type of Reporting Person (See Instructions)
CO
Comment for Type of Reporting Person: Note to Rows (5), (7) and (9): Represents 338,636 shares of the Issuer's common stock held by Simcere Zaiming, Inc., which is 100% owned by Jiangsu Simcere Zaiming Pharmaceutical Co., Ltd., which itself is 100% owned by Simcere Zaiming Pharmaceutical Co., Ltd. (formerly known as Hainan Simcere Zaiming Pharmaceutical Co., Ltd.) Pursuant to Section 13(d) of the Securities Exchange Act of 1934, as amended, and the rules promulgated thereunder, Simcere Zaiming Pharmaceutical Co., Ltd. may deemed to beneficially own all of the shares of the Issuer owned by Simcere Zaiming, Inc.
Note to Row (11): Based on an aggregate of 3,607,555 shares of the Issuer's common stock issued and outstanding as of April 22, 2026 as reported by the Issuer in its definitive proxy statement on Schedule 14A filed with the U.S. Securities and Exchange Commission on April 24, 2026.
SCHEDULE 13G
CUSIP Number(s):
65343E207
1
Names of Reporting Persons
Simcere Pharmaceutical Group Limited
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
CHINA
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
338,636.00
6
Shared Voting Power
0.00
7
Sole Dispositive Power
338,636.00
8
Shared Dispositive Power
0.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
338,636.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
9.4 %
12
Type of Reporting Person (See Instructions)
CO
Comment for Type of Reporting Person: Note to Rows (5), (7) and (9): Represents 338,636 shares of the Issuer's common stock held by Simcere Zaiming, Inc., which is 100% owned by Jiangsu Simcere Zaiming Pharmaceutical Co., Ltd., which itself is 100% owned by Simcere Zaiming Pharmaceutical Co., Ltd. (formerly known as Hainan Simcere Zaiming Pharmaceutical Co., Ltd.) Simcere Pharmaceutical Group Limited is the controlling shareholder of Simcere Zaiming Pharmaceutical Co., Ltd. through investment in several intermediate companies. Pursuant to Section 13(d) of the Securities Exchange Act of 1934, as amended, and the rules promulgated thereunder, Simcere Pharmaceutical Group Limited may be deemed to beneficially own all of the shares of the Issuer owned by Simcere Zaiming, Inc.
Note to Row (11): Based on an aggregate of 3,607,555 shares of the Issuer's common stock issued and outstanding as of April 22, 2026 as reported by the Issuer in its definitive proxy statement on Schedule 14A filed with the U.S. Securities and Exchange Commission on April 24, 2026.
SCHEDULE 13G
CUSIP Number(s):
65343E207
1
Names of Reporting Persons
Ren Jinsheng
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
CHINA
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
338,636.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
338,636.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
338,636.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
9.4 %
12
Type of Reporting Person (See Instructions)
IN
Comment for Type of Reporting Person: Note to Rows (6), (8) and (9): Represents 338,636 shares of the Issuer's common stock held by Simcere Zaiming, Inc., which is 100% owned by Jiangsu Simcere Zaiming Pharmaceutical Co., Ltd., which itself is 100% owned by Simcere Zaiming Pharmaceutical Co., Ltd. (formerly known as Hainan Simcere Zaiming Pharmaceutical Co., Ltd.) Mr. Jinsheng Ren is the chairman of the board of directors of Simcere Pharmaceutical Group Limited and a director of Simcere Zaiming Pharmaceutical Co., Ltd. Mr. Jinsheng Ren may thereby be deemed to beneficially own the 338,636 shares of the Issuer's common stock held by Simcere Zaiming, Inc., sharing the voting power and investment power over such shares with Mr. Renhong Tang.
Note to Row (11): Based on an aggregate of 3,607,555 shares of the Issuer's common stock issued and outstanding as of April 22, 2026 as reported by the Issuer in its definitive proxy statement on Schedule 14A filed with the U.S. Securities and Exchange Commission on April 24, 2026.
SCHEDULE 13G
CUSIP Number(s):
65343E207
1
Names of Reporting Persons
Tang Renhong
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
CHINA
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
338,636.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
338,636.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
338,636.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
9.4 %
12
Type of Reporting Person (See Instructions)
IN
Comment for Type of Reporting Person: Note to Rows (6), (8) and (9): Represents 338,636 shares of the Issuer's common stock held by Simcere Zaiming, Inc., which is 100% owned by Jiangsu Simcere Zaiming Pharmaceutical Co., Ltd., which is 100% owned by Simcere Zaiming Pharmaceutical Co., Ltd. (formerly known as Hainan Simcere Zaiming Pharmaceutical Co., Ltd.) Mr. Renhong Tang is a director of Simcere Pharmaceutical Group Limited, the chief executive officer and chairman of the board of directors of Simcere Zaiming Pharmaceutical Co., Ltd., a director of Jiangsu Simcere Zaiming Pharmaceutical Co., Ltd. and the chief executive officer and sole director of Simcere Zaiming, Inc. Accordingly, Mr. Renhong Tang may thereby be deemed to beneficially own the 338,636 shares of the Issuer's common stock held by Simcere Zaiming, Inc., sharing the voting power and investment power over such shares with Mr. Jinsheng Ren.
Note to Row (11): Based on an aggregate of 3,607,555 shares of the Issuer's common stock issued and outstanding as of April 22, 2026 as reported by the Issuer in its definitive proxy statement on Schedule 14A filed with the U.S. Securities and Exchange Commission on April 24, 2026.
SCHEDULE 13G
Item 1.
(a)
Name of issuer:
NextCure, Inc.
(b)
Address of issuer's principal executive offices:
9000 Virginia Manor Road, Suite 200, Beltsville, Maryland 20705
Item 2.
(a)
Name of person filing:
(i) Simcere Zaiming, Inc., a Delaware corporation ("Simcere Zaiming"), with its principal business address at 20 Acorn Park Dr., Cambridge, MA 02140;
(ii) Jiangsu Simcere Zaiming Pharmaceutical Co., Ltd., a limited liability company incorporated in P. R. China ("Jiangsu Zaiming"), is the sole shareholder of Simcere Zaiming, and its principal business address is at Building 23, No.699-18, Xuanwu Avenue, Nanjing, Jiangsu, P. R. China;
(iii) Simcere Zaiming Pharmaceutical Co., Ltd. (formerly known as Hainan Simcere Zaiming Pharmaceutical Co., Ltd.), a limited liability company incorporated in P. R. China ("Hainan Zaiming"), is the sole shareholder of Jiangsu Zaiming, and its principal business address is at No 20, Yaoguyiheng Road, Xiuying District, Haikou, Hainan, P. R. China;
(iv) Simcere Pharmaceutical Group Limited, a company incorporated in Hong Kong ("Simcere Group") and the controlling shareholder of Hainan Zaiming through several intermediate companies, and its principal business address is at Building 23, No.699-18, Xuanwu Avenue, Nanjing, Jiangsu, P. R. China;
(v) Mr. Jinsheng Ren, citizen of People's Republic of China, the chairman of board of directors and an executive director of Simcere Group and a director of Hainan Zaiming, with his business address at Building 23, No.699-18, Xuanwu Avenue, Nanjing, Jiangsu, P. R. China; and
(vi) Mr. Renhong Tang, citizen of People's Republic of China, a director of Simcere Group, the chief executive officer and chairman of the board of directors of Hainan Zaiming, a director of Jiangsu Zaiming and the chief executive officer and sole director of Simcere Zaiming, with his business address at Building 23, No.699-18, Xuanwu Avenue, Nanjing, Jiangsu, P. R. China.
The persons and entities listed in items (i) to (vi) are collectively referred to herein as "Reporting Persons." The Reporting Persons have entered into a joint filing agreement dated August 19, 2025.
(b)
Address or principal business office or, if none, residence:
See Item 2(a) above.
(c)
Citizenship:
See Item 2(a) above.
(d)
Title of class of securities:
Common Stock, par value $0.001 per share
(e)
CUSIP No.:
65343E207
Item 4.
Ownership
(a)
Amount beneficially owned:
See Row 9 of the cover page for each Reporting Person. Each of Reporting Persons disclaims beneficial ownership of the securities reported herein, except to the extent of such Reporting Person's pecuniary interest therein. The filing of this Amendment No.1 to Schedule 13G shall not be deemed to be an admission that the Reporting Persons hereunder are the beneficial owners of any of the reported securities for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended, or for any other purpose.
(b)
Percent of class:
See Row 11 of the cover page for each Reporting Person.
(c)
Number of shares as to which the person has:
(i) Sole power to vote or to direct the vote:
See Row 5 of the cover page for each Reporting Person.
(ii) Shared power to vote or to direct the vote:
See Row 6 of the cover page for each Reporting Person.
(iii) Sole power to dispose or to direct the disposition of:
See Row 7 of the cover page for each Reporting Person.
(iv) Shared power to dispose or to direct the disposition of:
See Row 8 of the cover page for each Reporting Person.
Item 5.
Ownership of 5 Percent or Less of a Class.
Not Applicable
Item 6.
Ownership of more than 5 Percent on Behalf of Another Person.
Not Applicable
Item 7.
Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
Not Applicable
Item 9.
Notice of Dissolution of Group.
Not Applicable
Item 10.
Certifications:
By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.
SIGNATURE
After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
Simcere Zaiming, Inc.
Signature:
/s/ Renhong Tang
Name/Title:
Renhong Tang/Chief Executive Officer
Date:
05/06/2026
Jiangsu Simcere Zaiming Pharmaceutical Co., Ltd.
Signature:
/s/ Renhong Tang
Name/Title:
Renhong Tang/Director and Attorney-in-Fact
Date:
05/06/2026
Simcere Zaiming Pharmaceutical Co., Ltd.
Signature:
/s/ Renhong Tang
Name/Title:
Renhong Tang/Chief Executive Officer and Chairman of the Board of Directors
Date:
05/06/2026
Simcere Pharmaceutical Group Limited
Signature:
/s/ Jinsheng Ren
Name/Title:
Jinsheng Ren/Chairman and Executive Director
Date:
05/06/2026
Ren Jinsheng
Signature:
/s/ Jinsheng Ren
Name/Title:
Jinsheng Ren
Date:
05/06/2026
Tang Renhong
Signature:
/s/ Renhong Tang
Name/Title:
Renhong Tang
Date:
05/06/2026
Comments accompanying signature: 24 Power of Attorney (incorporated by reference to Exhibit 24 to the Reporting Persons' Schedule 13G filed with the SEC on August 19, 2025).
99.1 Joint Filing Agreement, dated as of August 19, 2025, by and among the Reporting Persons (incorporated by reference to Exhibit 99.1 to the Reporting Persons' Schedule 13G filed with the SEC on August 19, 2025).
What stake in NextCure (NXTC) do the Simcere reporting persons disclose?
They disclose ownership of 338,636 shares, equal to 9.4% of NextCure's common stock. This percentage is calculated using 3,607,555 shares outstanding as of April 22, 2026 as cited in the filing.
Which entities and individuals filed the Schedule 13G/A for NXTC?
The filing is by Simcere Zaiming, Inc., Jiangsu Simcere Zaiming Pharmaceutical Co., Ltd., Simcere Zaiming Pharmaceutical Co., Ltd., Simcere Pharmaceutical Group Limited, and Messrs. Jinsheng Ren and Renhong Tang under a joint filing agreement.
Does the Schedule 13G/A state how voting or dispositive power is held?
Yes; the cover rows show sole or shared voting and dispositive power attributed to the Reporting Persons, with the filing noting shared voting/dispositive power for Messrs. Ren and Tang over the reported 338,636 shares.
Did the Reporting Persons claim full beneficial ownership of the shares?
No; each Reporting Person includes a standard disclaimer, stating they disclaim beneficial ownership except to the extent of any pecuniary interest, which is retained in the filing text and signatures.
What dates are relevant in this Schedule 13G/A amendment for NXTC?
The filing cites shares outstanding as of April 22, 2026 and shows signature dates of May 6, 2026. The joint filing agreement referenced is dated August 19, 2025.
